Female Sterilization Procedures - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The female sterilization procedures market size is expected to grow from USD 9.17 billion in 2025 to USD 9.64 billion in 2026 and is forecast to reach USD 12.37 billion by 2031 at 5.12% CAGR over 2026-2031. This report is segmented by Procedure Type (Surgical Sterilization and Non-Surgical or Transcervical Sterilization), End User (Hospitals and Maternity Centers, Ambulatory Surgical Centers, and More), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Female Sterilization Procedures Market Trends and Insights

Expanding Access to Permanent Contraception

Expanding hospital capacity across South Asia, Sub-Saharan Africa, and Latin America is expected to help convert unmet demand into completed procedures. Postpartum care serves as a key delivery channel, as providers can perform sterilization during cesarean delivery or shortly after birth. A 2024 multicenter U.S. study found that 41.6% of 3,013 patients who requested postpartum permanent contraception did not receive the procedure before discharge. Invalid Medicaid consent forms and limited operating room or physician availability each accounted for 27% of these unmet cases. In settings where public insurance covers the procedure, fulfillment rates approached 90%, demonstrating the role of coverage in converting stated preferences into treatment. The female sterilization procedures market stands to benefit as providers streamline consent processes, improve operating room access, and strengthen coordination between obstetric and surgical teams.

Government-Supported Family-Planning Programs

Public family-planning programs continue to underpin procedure volumes across many low- and middle-income countries. In fiscal year 2024, the U.S. government appropriated USD 607.5 million for international family-planning and reproductive health programs. This funding enabled access to modern contraceptive care for 47.6 million women and couples and helped prevent 17.1 million unintended pregnancies. However, the proposed withdrawal of U.S. international funding in 2026 may create a financing gap that other donors may be unable to offset, particularly as their combined contributions declined in 2024. India remains a significant demand center, with female sterilization accounting for 68.1% of the country’s modern contraceptive method mix in 2025. Public programs, including outreach initiatives in high-fertility districts, continue to support the female sterilization procedures market in India, while aid-dependent service systems face increasing uncertainty.

Irreversibility, Regret, and Informed-Consent Requirements

The permanent nature of sterilization requires comprehensive counseling and may delay or discourage procedure uptake. A nationally representative U.S. survey conducted in 2022 and 2023 found that 21.3% of women who underwent tubal sterilization wanted a reversal. Although this proportion declined from 26.8% in 2006, it remains a key consideration for patient counseling and service delivery. A 2024 Canadian study found that 15.9% of patients reported regret, 9.5% recalled coercive elements, and 33.3% did not recall discussing alternative methods before surgery. U.S. federal regulations require a 30-day waiting period for federally funded sterilization procedures. This requirement can affect postpartum procedure completion when patients are discharged before fulfilling the waiting-period requirement. These regulations may constrain elective procedure volumes among younger individuals, while increasing the need for structured counseling and access to reversible contraceptive alternatives.

Other drivers and restraints analyzed in the detailed report include:

• Shift Toward Minimally Invasive and Outpatient Procedures
• Opportunistic Salpingectomy for Ovarian-Cancer Risk Reduction
• Competition from Long-Acting Reversible Contraception

Segment Analysis

Surgical sterilization is expected to account for 63.54% of global procedure volume in 2025 and is projected to grow at a CAGR of 7.54% through 2031. This trend indicates that the largest procedure category will also be the fastest growing, with bilateral salpingectomy becoming more common than tubal ligation. In 2024, salpingectomies outnumbered tubal ligations by 3.3 to 1, compared with 1.2 to 1 in 2015. Within the female sterilization procedures market, this shift reflects broader clinical interest in reducing ovarian cancer risk. The female sterilization procedures industry is increasingly adopting complete fallopian tube removal in appropriate cases.

Non-surgical or transcervical sterilization is expected to represent the remaining 36.46% of procedure volume in 2025. However, the withdrawal of Essure in 2018 reduced patient and provider confidence in implant-based methods. Hysteroscopic tubal occlusion continues to serve a role in specialist centers that can provide office-based care. FemBloc is expected to receive approvals in Europe, the United Kingdom, and New Zealand in 2025. Femasys is expected to initiate enrollment for the U.S. FINALE pivotal trial in March 2026. U.S. approval could shift procedures toward clinic-based care among patients seeking an option that does not require anesthesia.

Complete Report Scope:

• By Procedure Type
  • Surgical Sterilization
    • Laparoscopic Tubal Surgery
    • Abdominal Tubal Surgery
    • Minilaparotomy
    • Partial Salpingectomy
    • Complete Bilateral Salpingectomy
  • Non-Surgical or Transcervical Sterilization
    • Hysteroscopic Tubal Occlusion
    • Transcervical Implant-Based Approaches
• By End User
  • Hospitals and Maternity Centers
  • Ambulatory Surgical Centers
  • Gynecology and Family-Planning Clinics
  • Other End Users
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America is projected to account for 42.43% of global procedure volume in 2025. The United States is expected to remain the region’s largest contributor, with female sterilization prevalence at 11.5% among women aged 15-49 in 2022 and 2023. Federal Title X funding totals USD 286.5 million for fiscal year 2025. However, the proposed elimination of the program in 2026 creates uncertainty for the 2.8 million low-income patients who accessed Title X-funded clinics in 2023. In abortion-restrictive states, monthly sterilization rates among women aged 18-25 remained 84% higher through 2023 following the Dobbs ruling. Canada has reported high satisfaction with postpartum sterilization; however, consent gaps continue to attract regulatory scrutiny in the female sterilization procedures market.

Asia-Pacific is projected to grow at a CAGR of 6.54% through 2031. India is expected to serve as the primary volume driver, with female sterilization accounting for 68.1% of its modern contraceptive method mix in 2025. Mission Parivar Vikas targets 146 high-fertility districts across seven states and supports the expansion of postpartum service delivery. While China has recorded declining tubal ligation volumes since 2015, Japan, South Korea, and Australia have established laparoscopic practices. Indonesia, Vietnam, and the Philippines are expected to support female sterilization procedures market growth as secondary hospital capacity expands and insurance coverage improves.

Europe is projected to hold the second-largest regional share in 2025, supported by mature surgical infrastructure. The European Union Medical Device Regulation’s clinical evaluation requirements may extend commercialization timelines for new tubal occlusion devices. However, FemBloc is expected to enter European markets in June 2025. Femasys is also expected to receive its first commercial order in Spain in August 2025, valued at USD 400,000. In Latin America, 33% of women of reproductive age in Colombia rely on female sterilization. Meanwhile, the Middle East and Africa face access constraints as foreign-aid reductions affect MSI programs across 31 countries. The female sterilization procedures market has the most uneven outlook in these settings, as demand does not consistently translate into the availability of surgical care.

List of Companies Covered in this Report:

• Apollo Hospitals Enterprise Limited
• Baylor Scott and White Health
• Cleveland Clinic
• Family Planning Association of India
• Fortis Healthcare
• Johns Hopkins Medicine
• Kaiser Permanente
• Marie Stopes International Kenya
• Mayo Clinic
• Mass General Brigham
• Manipali Health Enterprises Private Limited
• Mount Sinai Health System
• Narayana Health
• NYU Langone Health
• Planned Parenthood Federation of America
• UCSF Health
• Women's International Service for Health (MSI Reproductive Choices)
• EngenderHealth
• International Planned Parenthood Federation

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support